NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

This publication has 13 references indexed in Scilit:

• Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
  Nature Reviews Drug Discovery, 2010
• Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
  Journal of Medicinal Chemistry, 2010
• Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
  The Oncologist, 2009
• Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis
  Molecular Biology of the Cell, 2007
• A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1–Interacting Properties, in Patients with Advanced Solid Tumors
  Clinical Cancer Research, 2006
• Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications
  Virchows Archiv, 2005
• Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis
  Journal of Biological Chemistry, 2004
• Polo-like kinases and the orchestration of cell division
  Nature Reviews Molecular Cell Biology, 2004
• Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades
  The Prostate, 2004
• The polo‐like protein kinases Fnk and Snk associate with a Ca2+‐ and integrin‐binding protein and are regulated dynamically with synaptic plasticity
  The EMBO Journal, 1999